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In this issue of Immunity, Gras et al. (2009) provide structural hints on how acquisition of tolerance to a coex-
pressed MHC class I allele can deflect an antiviral response away from the immunodominant response.Antiviral CD8+ T cells recognize virus-
encoded peptides bound to major histo-
compatibility complex (MHC) class I
molecules, termed HLA A, B, and C in
humans and H-2 K, D, and L in mice.
MHC class I molecules present antigenic
peptides to the ab T cell antigen receptor
(TCR) expressed by CD8+ T cells. The
genes coding for MHC class I molecules
show an extraordinary degree of
polymorphism that primarily involves the
nucleotide sequences coding for the
peptide-binding domain and is thought
to reflect evolutionary pressure for recog-
nition of a repertoire of antigenic peptides
that is as broadly inclusive as possible.
Within a given species, MHC class I alleles
can differ from each other by more than
20 amino acids or by only a few amino
acids. TCR diversity is generated in the
thymus through site-specific DNA-
recombination reactions. The variable (V)
region of the a and b chains of the TCR
contains peptide loops that are homolo-
gous to immunoglobulin complemen-
tarity-determining regions (CDRs) and
that protrude at their membrane-distal
end, where they together form the binding
site for peptide-MHC (pMHC) complexes.
In contrast to the CDR1 and CDR2 loops
that are germline encoded and have
a weak intrinsic affinity for the top of the
a helices that line the MHC peptide-
binding domain, the amino acid
sequences that constitute the CDR3
loops are randomly assembled and can
thus confer to some TCRs the potential
for strong reactivity against self pMHC
complexes and thus the capacity to
initiate autoimmunity. Therefore, the
binding specificity of the clonally distri-
buted TCRs expressed on the surface of
developing T cells is tightly controlled so
that the emergence of pathogenic auto-
reactive T cells in the periphery is avoided.
No specific chemical attribute allows theMHC peptide-binding domain and the
TCR antigen-binding site to discriminate
self from non-self peptides. For devel-
oping T cells the definition of the immuno-
logic self constitutes an emergent
property that results from their ‘‘training’’
on self peptides bound to self MHC mole-
cules (Garcia et al., 2009; Mazza and Ma-
lissen, 2007). Such training selects those
TCRs that have a low affinity for self
pMHC complexes and deletes those that
are overtly self-reactive. Therefore, the
T cell immunologic self is specified de
novo in each individual during intrathymic
development and varies among individ-
uals on the basis of the inherited MHC
alleles and the repertoire of self peptides
capable of being presented in the thymus
by the products of these alleles. A study
by Gras et al. (Gras et al., 2009) in the
current issue of Immunity focuses on
two archetypal TCRs that originate from
unrelated individuals and recognize the
same viral peptide bound to HLA-B8
molecules. By comparing the structure
of the corresponding TCR-pMHC com-
plexes, Gras et al. found that these two
TCRs contact opposite sections of the
HLA-B8 surface. Acquisition of tolerance
to the product of an MHC class I allele
expressed in trans and irrelevant for the
HLA-B8-restricted antiviral response
was found responsible for such shifts in
TCR specificity.
Epstein-Barr Virus (EBV) is a virus of the
herpes family and causes lifelong infec-
tion in more than 90% of the human
population. The memory cytotoxic
T lymphocyte (CTL) response to the immu-
nodominant EBV peptide FLRGRAYGL
(abbreviated to FLR), which originates
from the latent viral antigen EBNA 3A and
associates with HLA-B8 molecules, is
dominated by CTL clones with identical
TCR V domain sequences (Burrows et al.,
1995). For instance, in unrelated HLA-B8+Immunity 30individuals, TCRs specific for the HLA-
B8-FLR complex use the same combina-
tion of Va-Ja (TRAV26-2*01, TRAJ52*01)
and Vb-Jb (TRBV7-8*03, TRBJ2-7*01)
gene segments and show conserved
CDR3 loops. Analysis of one such ‘‘public’’
TCR, denoted LC13 (Kjer-Nielsen et al.,
2003), showed that it focused on amino
acid residues found at positions 6, 7, and
8 of the EBV peptide and on the carboxy-
terminal end of the HLA-B8 peptide-
binding domain (Figure 1).
Peripheral T cells normally interact with
dendritic cells and target cells (B cells,
parenchymal cells, and others) bearing
MHC alleles that match those present in
the thymic environment. However under
experimental or clinical conditions, TCRs
can also react against MHC molecules
not seen during thymic selection. For
instance, during graft rejection and
graft-versus-host disease, many TCRs
recognize intraspecies allelic variants of
self-MHC molecules. This capacity,
termed alloreactivity, also concerns the
LC13 TCR because it recognized the
B*4402 allele of the HLA-B44 supertypic
family (Burrows et al., 1995). For LC13,
such alloreactivity was documented with
EBV-uninfected cells and thus involves
endogenous peptides bound to the HLA-
B*4402 allelic product. A parsimonious
interpretation of the structure of a TCR
bound to an allogeneic MHC molecule
suggests that alloreactive TCRs exploit
the similarities rather than the differences
existing between the top of the a helices
of self and allogenic MHC molecules (Re-
iser et al., 2000). Along that line, LC13
alloreactivity is also thought to involve
a surface of the HLA-B*4402 peptide-
binding domain that mimics the structural
determinant recognized by LC13 on HLA-
B8 (Burrows et al., 1995). No CTL clones
expressing LC13-like TCRs are found in
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Figure 1. The Recognition of HLA-B8 Molecules by the LC13 and CF34 TCRs
The TCRs contact residues located on the top of the MHC a helices (depicted as black parenthesis) are
represented as squares, triangles and circles and can differ between MHC alleles. The TCRs also scan
MHC-bound peptides (depicted as purple (HLA-B8 allele) or green (HLA-B*4402 allele) wavy ribbon). In
the case of the HLA-B8 and HLA-B*4402 MHC alleles, the constellation of TCR-accessible residues found
at the amino-terminal (N) end of their peptide-binding domains differ. In contrast, those found at the car-
boxy-terminal (C) end of their peptide-binding domains are conserved and allow the LC13 TCR to recog-
nize both the FLR viral peptide bound to self HLA-B8 molecules and the HLA-B*4402 molecules expressed
by other individuals and bound to endogeneous (self) peptides. The docking solution adopted by the CF34
TCR differs from that of LC13 TCR in that it avoids binding to an HLA-B8 area that mimics a structure
present on HLA-B*4402. As a result, it lowers its probability of being negatively selected by the self
HLA-B*4402 molecules that are present in HLA-B8+, HLA-B*4402+ heterozygous individuals and allows
it to contribute to anti-EBV responses.individuals coexpressing the HLA-B8 and
HLA-B*4402 alleles, presumably as a
result of their ability to strongly react to
self peptides bound to HLA-B*4402 and
thereby to be deleted during T cell devel-
opment (Burrows et al., 1995). If in HLA-
B8+, HLA-B*4402+ individuals, CD8+
T cells expressing LC13-like TCRs were
to slip through the mechanisms that main-
tain central tolerance, recognition of HLA-
B*4402 complexed to self peptides and
expressed by immature dendritic cells
would probably result in abortive CTL
responses. However, after EBV infection
and priming of CTL clones expressing
L13-like TCRs, an autoimmune response
might ensue.
In HLA-B8+, HLA-B*4402+ individuals,
deletion of the CTL clones that use
LC13-like TCRs and dominate the
memory response of HLA-B8+, HLA-
B*4402- individuals might create a ‘‘hole
in the repertoire’’ and prevent subsequent
anti-FLR responses. As demonstrated by
Burrows et al. (Burrows et al., 1995), the
TCR repertoire is, however, sufficiently
flexible to compensate for this loss;
HLA-B8+, HLA-B*4402+ individuals are
still capable of mounting a robust HLA-
B8-restricted CTL response toward the
FLR peptide. Among the HLA-B8-FLR-
specific CTL clones that were observed
in unrelated individuals expressing HLA-
B8 and HLA-B*4402 alleles, several
shared a public TCR that uses Va
(TRAV14*01) and Vb (TRBV11-2*03)170 Immunity 30, February 20, 2009 ª2009 Egene segments. As expected for CTL
clones expressing TCRs selected in
HLA-B8+, HLA-B*4402+ individuals, none
of them reacted against self-HLA-
B*4402 molecules bound to self peptides.
In this issue, Gras et al. (Gras et al., 2009)
report the structure of one of those public
TCRs, CF34, in complex with the HLA-B8-
FLR pMHC ligand. Comparison of the
structure of the LC13-FLR-HLA-B8 and
CF34-FLR-HLA-B8 complexes showed
that both of them docked onto HLA-B8
according to the roughly diagonal binding
mode observed in most of the existing
TCR-pMHC structures. Such a docking
mode allows the relatively flat TCR-
binding surface to ‘‘slot’’ between the
high ‘‘peaks’’ that are found near the
amino termini of each of the two MHC
class I a helices, and it thus maximizes
the readout of the few peptide residues
that are exposed to the TCR (Rudolph
et al., 2006). Flow-cytometric analysis
performed with HLA-B8 tetramers that
incorporated analogs of the FLR peptide
with substitutions at position 1 and 8
showed that CF34 differs from LC13 in
that it is affected by the mutation involving
the amino-terminal end of the viral
peptide. Consistent with such analysis,
the structure of the CF34-FLR-HLA-B8
complex showed that CF34 recognized
residues found at positions 1 to 7 of the
FLR peptide and that its ‘‘footprint’’ on
the MHC surface was more amino-termi-
nally focused than that of LC13 (Figure 1).lsevier Inc.Inspection of the residues that are both
polymorphic between HLA-B8 and HLA-
B*4402 and accessible to TCR contact
suggested a rationale for the docking
mode adopted by the CF34 TCR upon
recognition of the HLA-B8-FLR complex.
Among the 24 polymorphic residues that
distinguish HLA-B*4402 from HLA-B8,
only five mapped on the top of the MHC
a helices that line the peptide-binding
groove and can thus be directly contacted
by the TCR. Interestingly, the subset of
polymorphic MHC residues that clusters
at the amino-terminal end of the
peptide-binding domain was found to
constitute one sizeable contact point
used by the CF34 TCR. Therefore, CF34
focused on an area of HLA-B8 that is
structurally divergent from that present
in HLA-B*4402 (Figure 1). By adopting
such an amino-terminal footprint, CF34
avoided binding to the carboxy-terminal
section of the HLA-B8 surface that mimics
a structure present on HLA-B*4402 and
thereby lowered its probability of being
negatively selected. Such conclusions
support the views raised by Burrows
et al. (Burrows et al., 1995) one year
before the first structure of a TCR-pMHC
complex was reported. However,
because a recent study showed that a
given TCR can adopt markedly distinct
docking strategies in recognizing a self
and allogeneic MHC class I molecules
(Colf et al., 2007), it should be stressed
that to be fully substantiated the conclu-
sions reached by Gras et al. (Gras et al.,
2009) will require the resolution of the
structure of an LC13-HLA-B*4402 com-
plex and thus a formal demonstration
that LC13 binding does indeed exploit
the similarities that exist between HLA-
B8 and HLA-B*4402.
In conclusion, the structural study by
Gras et al. (Gras et al., 2009) illustrates
how acquisition of tolerance to the
product of an MHC class I allele
expressed in trans and irrelevant for anti-
EBV responses led to the refocusing of
the entire anti-EBV memory response.
As a result, a new hierarchy in TCR usage
is established such that CTL clones
expressing alternative TCRs emerge and
are no longer dominated by those
expressing a canonical public TCR. There-
fore, regardless of the fact that T cell
specificity directly stems from the struc-
ture of the antigen-binding site of TCR V
domains, prediction of the TCR repertoire
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Previewsto be used during a given immune
response is a daunting task because it
can only be achieved through the integra-
tion of a wealth of information collected at
both the structural and organismal levels.
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The ability of dendritic cells (DCs) to stimu-
late T cell responses is regulated by
external cues. Resting (immature) DCs,
which are poor activators of T cells, can
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CD40, which is expressed constitutively
on DCs, and CD40L (also known as
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occurring via a distinct mechanism. In this
context, Johnson et al. (2009) now provide
evidence that one way in which viruses
stimulate helper-independent CD8+ T cell
responses is by inducing CD40L expres-
sion on DC, which then triggers CD40
expressed on activated CD8+ T cells.
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from experiments investigating the ability
of antagonistic CD40L antibodies to
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responses in mice. Their measurements
focused on the generation of primary
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anti-CD40 treatment was used to replace
CD4+ T cell help. These results indicated
that CD40L expression on something
other than a CD4+ T cell could promote
CD8+ T cell priming. Subsequently, the
authors observed that splenic DCs
expressed substantial amounts of CD40L
after overnight in vitro culture, conditions
known to induce DC activation. Because
activated CD8+ T cells were shown to
express CD40, this led to the hypothesis
that DC-expressed CD40L promoted the
CTL response by binding to CD40 on
CD8+ T cells.
Evidence supporting this hypothesis
was generated in in vitro assays, in which
purified splenic DCs were used to stimu-
late allogeneic CD8+ T cells. Here,
CD40L-deficient (Cd40Ig/) DCs were
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